Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biotechnology

Conagen makes strides in biobased chemicals

by Michael McCoy
May 2, 2021 | A version of this story appeared in Volume 99, Issue 16

The structure of capsaicin.

The industrial fermentation specialist Conagen says it has developed a process for making capsaicinoid compounds; the firm is separately offering production services to another biobased chemical developer. The Bedford, Massachusetts–based firm says it has successfully scaled up a process for making capsaicin and related molecules such as dihydrocapsaicin and nonivamide, a capsaicinoid used in topical muscle pain relievers and in synthetic pepper spray. Capsaicin and dihydrocapsaicin are responsible for about 90% of the pungency in chili pepper, the firm says. Meanwhile, Conagen has signed an agreement to make the amino acid L-alanine for the fermentation specialist DMC Biotechnologies. In March, DMC said it had demonstrated commercial-scale production of L-alanine with another partner, the German firm EW Biotech. Conagen, cofounded in 2010 by the biochemist Oliver Yu, also has deals with BASF and Sumitomo Chemical.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.